The MDR1 gene and Its Transcript P-glycoprotein Expressions in Lung Cancer by Hirose Kiyoto
Acta Med. Nagasaki 39:59-64
The MDR1 gene and Its Transcript P-glycoprotein 
Expressions in Lung Cancer
Kiyoto HIROSE 
The Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan.
To determine the clinical significance of the MDR1 gene and 
its transcript P-glycoprotein (PGP) expression in lung 
cancer, ninety-one surgical lung cancer samples and normal 
lung tissues were analyzed. They consisted of 85 NSCLC (84 
untreated and one treated) and 6 SCLC (three untreated and 
three treated). MDR1 messenger RNA (mRNA) levels in all 
surgical samples were determined by Northern blotting and 
compared with anticancer drug-sensitive and -resistant cell 
lines. The transcript PGP was detected in frozen sections by 
immunohistochemical staining. There was a strong correla-
tion between the levels of MDR1 mRNA and PGP expression 
in the tumors. No normal lung tissues expressed the MDR1 
gene in Northern blots. Fifteen percent (13/87) of the un-
treated tumors were positive for the MDR1 gene at low levels, 
which did not relate to any pathologic factors such as 
histologic type, tumor extensions, and differentiation grade. 
All three treated SCLC expressed high levels of the MDR1 
gene, although all three untreated SCLC did not. Further-
more, only SCLC negative for MDR1 gene tended to respond 
to chemotherapy. The MDRI gene is thought to be related to 
multidrug resistance in SCLC. A prospective study in a large 
number of patients should be attempted to clarify the clinical 
significance of the MDR1 gene in the treatment of SCLC. 
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ABBREVIATIONS 
MDR=multidrug resistance; PGP=P-glycoprotein; 
NSCLC=non-small-cell lung cancer; SCLC=small-cell lung 
cancer; mRNA=messenger RNA
  Lung cancer is one of the most common human cancers 
in the world, the rate of which is increasing. Among human 
cancers, its mortality is comparatively high, despite 
extensive investigations and intensive chemotherapy.' 
Multidrug resistance (MDR) against anticancer drugs is 
the most serious problem encountered in treating lung 
cancer as well as other cancers." The MDR1 gene encoding
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P-glycoprotein (PGP), acting as an energy-dependent drug 
efflux pump, is the molecular basis for drug resistance. I` 
P-glycoprotein-transported drugs (or MDRI-related drugs) 
are lipophillic compounds such as anthracycline antibiot-
ics, vinca alkaloids, and podophyllotoxins z, which are key 
drugs in cancer chemotherapy. 
 The MDR1 gene and its transcript PGP are expressed in 
many normal tissues and tumors at various levels." 
Tumors that originate from tissues, which express essen-
tially high levels of MDR1 gene, tend to express high levels 
of the MDR1 gene.'" Normal lung tissue and most lung 
tumors express low levels of MDR1 gene, compared with 
the colon, kidney, and adrenal gland. 10.11 However, the role 
of the MDRI gene in acquired drug resistance or 
heterogenous MDR1 expression in solid tumors including 
lung cancer have not yet been clarified. 
 We examined the expression of the MDR1 gene and its 
transcript PGP, by Northern blotting and immuno-
histochemical staining, in surgical lung cancer samples to 
determine their clinical significance in lung cancer. 
MATERIALS AND METHODS 
Tumor samples 
 Ninety-one surgical lung cancer samples were obtained 
from Nagasaki University Hospital and its satellite 
hospitals, and immediately frozen in liquid nitrogen and 
stored at -70°C until processing. From several lung cancer 
patients, normal lung tissues were obtained simultane-
ously. Some of the tumor samples were obtained for 
accurate diagnosis rather than for surgical treatment. The 
patients consisted of 62 males and 29 females, and the 
mean age was 64 years ranging from 34 to 81. The 
histologic types were 53 adenocarcinoma, 29 squamous cell 
carcinoma, 3 large cell carcinoma, and 6 SCLC. Four of 
them, one adenocarcinoma and three SCLC, had received 
MDR1-related anticancer drugs before surgery. 
 The histologic type and grade of differentiation were 
classified according to World Health Organization 
histologic classif ication. 12 The postsurgical pathologic
stage, including computed tomography, magnetic reso-
nance imaging, and radionuclide scan, was determined 
according to the International Union Against Cancer 
staging system. 13 
Cell lines 
 The KB-3-1 cell line is a drug-sensitive parental line 
originated from HeLa cells. The drug-resistant KB-8-5 and 
KB-C1 cell lines, which express high levels of MDR1 
mRNA without gene amplification, were derived from 
KB-3-1 by continuous exposure to colchicine. ' They are 3 
and 160 times as resistant to doxorubicin, and 6 and 96 
times as resistant to vinblastine as the parental line, 
respectively. s, 15 All KB cell lines were provided by Dr. 
Shinichi Akiyama (Kagoshima University, Kagoshima, 
Japan). 
Northern blot analysis 
 Total RNA was isolated from tissues and culture cells 
using guanidium thiocyanate method. 16 RNA (10 y g per 
lane) was analyzed by standard Northern blot hybridiza-
tion 17, in which the human MDR1 probe was the 2.2-kbp 
EcoRI-Pst I fragment from clone pMDRA1 that originated 
from a human adrenal gland. 18 The probe was provided by 
Dr. Kazumitsu Ueda (Kyoto University, Kyoto, Japan). 
Autoradiographs were visualized using an Imaging Plate 
type BAS-III (Fuji Photo Film Co., Kanagawa, Japan) for 
about three hours. All membranes were rehybridized in a 
similar manner with a beta-actin probe. 
 The MDR1 mRNA levels of all samples were determined 
by scanning the autographic bands and comparing them 
with beta-actin mRNA, using a Bio-Image Analyzer 
BAS2000(Fuji Photo Film Co., Kanagawa, Japan). The 
latter was a control for the amount of RNA on the 
membranes. The levels were recorded on a scale of "-" to 
"++"
, where "-"(negative) corresponded to the level in 
the KB-3-1 cell line, " + " (low level) to an intermediate 
level between KB-3-1 and KB-8-5, and "+ +"(high level) to 
a level higher than that in KB-8-5.
Immunohistochemical Staining for PGP 
 Frozen sections of normal lung tissues and the tumors 
were prepared and processed by standard procedures. 19 The 
sections were incubated overnight at 4 °C with the C219 
mouse monoclonal antibody (Centocor, Malvern, U.S.A.) 
that recognizes the epitope in the cytoplasmic domain of 
PGP. 20 Subsequently, they were incubated with goat 
antimouse IgG conjugated horseradish peroxidase (Vector 
Laboratories, Burlingame, U.S.A.), and stained with 3,3 
diaminobenzydine tetrahydrochloride. For every staining, 
KB-8-5 and KB-3-1 cells prepared by a cytocentrifuge were 
used as positive and negative controls, respectively. The
results were separately evaluated by two pathologists. 
Data Analysis 
 All results were statistically evaluated by the chisquared 
test. A two-tailed P<0.05 was considered to indicate 
statistical significance.
RESULTS 
 Figure 1 shows a Northern blot of the MDR1 gene in the 
control KB cell lines, the normal lung tissues, and the 
tumors, which were compared with one adrenocortical 
adenoma, and one renal cell carcinoma. In the KB lines, the 
MDR1 mRNA expression levels correlated with the degree 
of resistance to anticancer drugs. Among three types of 
tumor, adrenocortical adenoma expressed the highest level 
of MDR1 mRNA. The lung tumors expressed various levels 
of MDR1 mRNA ranging from negative to high, whereas 
it was undetectable in normal lung tissues.
Figure 1. Northern blots of MDR1 gene expression in lung 
cancer. A 10 ,u g of total RNA from cell lines and tumor 
samples was used in each lane. Lane 1, normal lung tissue; 
lane 2, lung adenocarcinoma (negative); lane 3, large-cell 
carcinoma (low level); lane 4, small-cell carcinoma (high 
level); lane 5, adrenal tumor, lane 6 ; renal cell carcinoma. 
Hybridization with a beta-actin probe provided comparable 
amounts of RNA loaded in each lane. KB-3-1 = drug-sensitive 
parental cell line; KB-8-5 and KB-C1=drug-resistant KB cell 
lines.
 Table 1 shows the MDR1 gene expressionin 87 previously 
untreated lung cancers. Fifteen percent (13/87), which 
were all NSCLC, were positive for the MDR1 gene, and all 
three SCLC were negative. Only one adenocarcinoma of 13 
positives was at a high level, and the remaining twelve at 
low levels, as shown in Table 3. There was no statistical 
difference between MDR1 gene expression and histologic 
type. 
 Table 2 shows the relationship between MDR1 gene
Table 1. Incidence of MDR1 Gene Expression in Lung 
Cancer* 
 Histology No. of patients Positive(%) t 
 Non-small-cell carcinoma 84 13(15) 
   adenocarcinoma 52 8(15) 
   squamous carcinoma 29 4(14) 
   large-cell carcinoma 3 1(33) 
 Small-cell carcinoma 3 0( 0) 
 Tatal 87 13(15) 
* None of the patients had received anticancer drugs. 
t No statistival correlation between MDR1 gene expression 
 and histologic type.
Table 2. MDRI Gene Expression and Pathologic Factors in 
NSCLC * 
 Factors No.of patients Positive (%) f 
 p-Stage (n=80) 
   I 30 5(17) 
  II 12 2(17) 
  I11 A 22 4(18) 
  IQ B 6 1(16) 
  IV 10 1(10) 
 T-factor (n=80) 
  T1 25 3(12) 
  T2 38 9(24) 
  T3 11 0( 0) 
  T4 6 1(17) 
 N-factor (n=80) 
  NO 45 5(11) 
  Ni 11 3(27) 
  N2 24 5(21) 
 Differentiation (n=80) 
  well 29 5(17) 
   moderately 27 3(11) 
  poorly 14 4(29) 
   unknown 10 -
* None of the patients had received anticancer drugs. 
fi No statistical correlations between MDRI gene expression 
 and any factors.
expression and pathologic factors in 80 untreated NSCLC, 
in which the pathologic stages were determined. There 
were no statistical correlations between MDR1 gene 
expression and pathologic factors such as pathologic 
stage, T factor, N factor, and differentiation grade. Even 
within each histologic type of NSCLC, no statistical 
differences among factors were seen. 
 Table 3 shows all sixteen MDR1 gene positives in this 
study. Three SCLC had received anticancer drugs and 
expressed high levels of the MDR1 gene, although a treated 
adenocarcinoma was negative. Patient No.14 had been 
treated with a CAV (cyclophosphamide, doxorubicin, and 
vincristine) regimen before surgery, and did not respond to 
chemotherapy at recurrence. The other two SCLC had been 
treated with cisplatin and VP-16 for neo-adjuvant chemo-
therapy, and patient No.15 expressed the highest level of 
MDRI gene among these positives.
Table 3. Lung Cancer Patients Positive for the MDR1 Gene 
Patient No. Sex Age Histology Defferentiation p-TNM MDR1level` 
  1 m 55 adeno poorly 220 + 
  2 m 58 adeno well 100 + 
  3 m 62 adeno well 220 + 
  4 f 46 adeno well 100 + 
  5 m 62 adeno poorly 200 + 
  6 m 55 adeno moderately 210 + 
  7 f 52 adeno well 220 + 
  8 f 70 adeno moderately 100 + + 
  9 m 71 squamous well 410 +
 10 m 73 squamous moderately 200 + 
 11 m 59 squamous poorly 200 + 
 12 f 75 squamous poorly 220 + 
 13 f 64 large - 221 + 
 14 f m 59 small - 401 + + 
 15t m 61 small - 320 + + 
 16 t m 58 small - 220 + + 
* A low level (+) of MDR1 gene expression corresponds to 
 an intermediate level between KB-3-1 and KB-8-5, and a 
 high level (+ +) to a level higher than that in KB-8-5. (see 
 Materials and Methods in text) 
t Patients had received MDR1-related anticancer drugs.
Table 4. MDR1 Gene Expression and Response to 
Chemotherapy* 
 Response NSCLC (n = 9) SCLC (n= 3) 
 Non-responder 2/2(100%)
. 1/1(100%)  MDR1 positive 
   responder 1/7(14%) 2/2(100%) 
 MDR1 negative 
* Patients received MDR1-related anticancer drugs at recur-
 rence or after surgery. The responder was a patient whose 
 tumor was reduced by over 50% after chemotherapy.
 The control cell lines and some of the tumors expressing 
low and high levels of MDR1 gene in Northern blots, were 
stained with C219 antibody (Figure 2). In normal tissue 
only bronchial epithelium was positively stained, and the 
cancer cells in the tumor were heterogeneously positive 
as shown in Figures 2C and 2D. The cancer cells in patient 
No.15 with SCLC were heterogeneously and strongly 
positive (Figure 2D). The level of MDR1 gene expression 
in the Northern blots correlated with those of PGP expres-
sion in the tumors. 
 Table 4 shows the relationship between MDRI gene 
expression and the response to chemotherapy. Subsequent 
responses to chemotherapy at recurrence or after surgery 
were evaluated in twelve patients. Six NSCLC negative for 
the MDR1 gene and two positive NSCLC did not respond to 
MDR1-related drugs, and only one negative NSCLC re-
sponded. One positive SCLC, treated previously, did not 
respond to chemotherapy, although two negative SCLC 
untreated did.
Figure 2. Immunohistochemical staining of P-glycoprotein (PGP) in control cell lines and lung cancer.(A) KB-8-5 cells of the 
positive control are positively stained in the cytoplasm.(B) KB-3-1 of negative control.(C) In the adenocarcinoma, some of the 
cancer cells are positively stained, and some of them are negative (lower right).(D) In patient No. 15 with SCLC, most cancer 
cells are strongly stained (upper), and some of them are negative or weakly stained (left). 
(original magnification: A, x200; B, x200; C, x200; D,x300)
DISCUSSION 
 Multidrug resistance is one of the most serious problems 
in the treatment of lung, as well as other human cancers 
.1,2 The MDR1 gene, one molecular basis for drug resis-
tance, and its transcript PGP, have been extensively 
examined in normal human tissues and tumors. 6 9 Tumors 
originating from tissues which express essentially high 
levels of MDR1 gene tend to express high levels of the 
MDR1 gene, such as colon, kidney, adrenal gland, and 
pancreatic tumors." 7 Normal lung tissue and most lung 
tumors reportedly express low levels of the MDR1 gene 
and PGP.8-11 However, the role of the MDR1 gene in 
acquired drug resistance or heterogeneous MDR1 gene 
expression in solid tumors including lung cancer have not 
been sufficiently clarified. All the treated SCLC in this 
study expressed high levels of the MDR1 gene, although
only fourteen percent (12/87) of the untreated tumors 
expressed low levels. 
 The level of the MDR1 gene in clinical samples is deter-
mined by Northern or slot-blot analysis, polymerase chain 
reaction (PCR), RNAse protection assay, and in situ 
hybridization.","', 21 Western blotting, immunohisto-
chemical staining, and flow cytometry are used to detect 
PGP. & 9, 22 These methods vary considerably in their sensi-
tivity, specificity, and quantitation. 22 At least two meth-
ods should be used, because evaluation of the MDR1 gene 
or PGP expression depends on the detection method. To 
detect MDR1 gene expression in individual cancer cells is 
quite important, because cells expressing the MDR1 gene 
survive and relapse, despite intensive chemotherapy with 
MDR1-related drugs. Northern blots and immunohisto-
chemical staining in frozen sections were compared in this 
study. The levels of MDR1 gene expression determined by 
Northern blotting correlated with those of PGP expressed
heterogenously in the tumors (Figure 2). 
 Only fifteen percent (13/84) of the untreated NSCLC 
were positive for the MDR1 gene, one of which was highly 
positive and the others marginally so, regardless of any 
pathologic factors (Table 3). The MDR1 gene is unlikely 
to relate to drug resistance in NSCLC 10, 2 , 24, because the 
response rate to chemotherapy is low, ranging from 20 to 
55%, despite the low level of MDR1 gene expression',', 
suggesting the existence of other MDR mechanisms. zs Six 
out of seven negative NSCLC for MDRI gene in this study 
did not respond to chemotherapy with MDR1-related 
drugs. However, the role of the MDR1 gene in SCLC 
remains controversial, apart from other drug resistance 
mechanisms. 10,26-29 The results (Tables 2 and 4), suggested 
that the MDRI gene is associated with drug resistance in 
SCLC. The MDR1 gene in lung cancer should be examined 
separately in NSCLC and in SCLC, because their biological 
and clinical behavior differs.' 
 Most cancer cells are heterogeneous with regard to 
immunogenicity, growth rates, and sensitivity to 
anticancer drugs, including MDR1 gene expression. 23, 31 The 
MDR1 gene in SCLC has been studied in cell lines estab-
lished from treated and untreated clinical samples. 7, 10, 27, 28 
Whereas our results from clinical samples were similar to 
those of previous studies using untreated SCLC, they were 
different from those using treated SCLC.10,27 The possibil-
ity remains that the cell lines established from treated 
SCLC were MDR1 gene negative clones. 
  Drug-sensitive cancer cell lines in vitro can acquire 
resistance to several cytotoxic drugs',',', although it is 
unclear whether the clinical dose of anticancer drugs 
induces acquired resistance in MDR1 gene-negative cancer 
cells. Those that acquired MDR1 related-resistance might 
heve biological aggressiveness and metastatic potent-
ial. 32, 33 To detect MDRI gene expression in SCLC following 
intensive chemotherapy would be important in predicting 
prognosis and attempting new clinical trials. MDR1 gene 
expression is reportedly a negative prognostic factor in 
hematolymphoid malignancies, such as acute myeloid 
leukemia (AML), lymphoma, and multiple myeloma. ° 
Several clinical trials, using chemosensitizing agents, for 
these cancers have been attempted to reverse the 
MDR. 34, 35 For SCLC which do not respond completely to 
chemotherapy, such trials might be worthwhile in the 
future. 
 In conclusion, the MDR1 gene is thought to be related to 
multidrug resistance in SCLC. A prospective study of a 
large number of patients should be attempted to clarify 
the clinical significance of MDR1 gene in the treatment of 
SCLC. 
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